For Patients with Multiple Myeloma, DTP3 May Be Effective

Share this content:

the Cancer Therapy Advisor take:

According to a study published in the journal Cancer Cell, researchers at Imperial College London in London, United Kingdom, have developed a novel cancer drug called DTP3 that has effectively killed myeloma cells in human cells and mice during laboratory tests. The drug did not cause any toxic adverse effects, a common problem with most other anticancer drugs. DTP3 works by inhibiting an important process involved with cancer cell proliferation.

By studying cancer cells from patients with multiple myeloma, the researchers identified GADD45β/MKK7, a protein complex that plays a key role in helping cancer cells to survive.

By targeting this protein complex with DTP3, the nuclear factor kappa B (NF-kB) signaling pathway, which is overactive in numerous types of cancer and responsible for preventing apoptosis, becomes interrupted, thereby leading to selective myeloma cell death. A key benefit of DTP3 is that it does not result in toxic side effects at the doses that have destroyed tumors in mice.

The researchers are optimistic that DTP3 could have therapeutic benefit for the treatment of patients with multiple myeloma and possibly other types of cancer. They hope to begin clinical trials next year.

Life expectancy is a significant indicator of future mortality risk and additional care in patients
A novel cancer drug called DTP3 has effectively killed myeloma cells in human cells.

Scientists at Imperial College London have developed a new cancer drug which they plan to trial in multiple myeloma patients by the end of next year. In a paper published today in the journal Cancer Cell, the researchers report how the drug, known as DTP3, kills myeloma cells in laboratory tests in human cells and mice, without causing any toxic side effects, which is the main problem with most other cancer drugs.

The new drug works by stopping a key process that allows cancer cells to multiply. The team have been awarded Biomedical Catalyst funding from the Medical Research Council (MRC) to take the drug into a clinical trial in multiple myeloma patients, scheduled to begin in late 2015. Multiple myeloma is an incurable cancer of the bone marrow, which accounts for nearly two per cent of all cancer deaths.

READ FULL ARTICLE From Medical News Today

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs